EUPHRATES, an RCT performed in the USA and Canada on Polymyxin B hemoperfusion therapy (Toraymyxin®) has finished enrolment and the first results on the primary endpoints have recently been announced in a press release.

Dr. Bert Spilker, Chairman of the Data Safety Monitoring Board:

“The trial clearly showed that the Toraymyxin® medical device is safe and, even though statistically significant reduction in 28 day mortality was not achieved with this sample size, the 5% mortality reduction in the per protocol population combined with the other positive benefits observed in treated septic shock patients is encouraging”.

For further analysis of the data, we are awaiting the publication, not currently available.